Aptcash Enterprises
Parel, Mumbai, Maharashtra
GST No. 27BDTPM3418D1ZF
TrustSEAL Verified
View Mobile No.
SEND EMAIL

Cancer Medicine Drugs

We are a leading Wholesale Trader of bevacizumab abevmy 400mg 100 mg injection mylan, abirapro (abiraterone acetate) 250mg and curcumin - curgneet liquid from Mumbai, India.

Bevacizumab Abevmy 400mg 100 Mg Injection Mylan

Bevacizumab Abevmy 400mg 100 Mg Injection Mylan
  • Bevacizumab Abevmy 400mg 100 Mg Injection Mylan
  • Bevacizumab Abevmy 400mg 100 Mg Injection Mylan
  • Bevacizumab Abevmy 400mg 100 Mg Injection Mylan
Get Best Quote
Approx. Price: Rs 90 / PieceGet Latest Price

Product Details:

Packaging Size400mg,100mg inj
BrandAbevmy
CompositionBevacizumab
ManufacturerMylan
Packaging400mg,100mg vial
Treatmentcolon cancer,lung cancer,glioblastoma,and renal-cell carcinoma. For age-related macular degenerat
Dosage Form400mg 100mg inj
Warning and PrecautionBevacizumab inhibits the growth of blood vessels,which is part of the body's normal healing and mai
FormInjection
Therapeutic Usescolorectal cancer,some cases Lung cancer,Breast cancer,Renal cancers,Brain cancers,Eye disease,Ovar
Side Effecthypertension and heightened risk of bleeding. Bowel perforation,Fatigue and infection
Strength400mg,100mg inj

Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age-related macular degeneration it is given by injection into the eye.

Common side effects when used for cancer include nose bleeds, headache, high blood pressure, and rash.Other severe side effects include gastrointestinal perforation, bleeding, allergic reactions, blood clots, and an increased risk of infection.When used for eye disease side effects can include vision loss and retinal detachment.Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor.It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A), in other words anti-VEGF therapy.

Bevacizumab was approved for medical use in the United States in 2004.It is on the World Health Organization''s List of Essential Medicines, the safest and most effective medicines needed in a health system.It is listed for its use in treating eye disease.
Contents

Medical uses

Colorectal cancer
Bevacizumab was approved in the United States in February 2004, for use in metastatic colorectal cancer when used with standard chemotherapy treatment (as first-line treatment) and with 5-fluorouracil-based therapy for second-line metastatic colorectal cancer.[citation needed]
It was approved by the European Medicines Agency (EMA) in January 2005, for use in colorectal cancer.
Also can be used some cases Lung cancer,Breast cancer,Renal cancers,Brain cancers,Eye disease,Ovarian cancer.

Administration
Bevacizumab is usually given intravenously every 14 days. In colon cancer, it is given in combination with the chemotherapy drug 5-FU (5-fluorouracil), leucovorin, and oxaliplatin or irinotecan.[medical citation needed] For treatment of eye diseases it is injected intravitreously.

Adverse effects

Bevacizumab inhibits the growth of blood vessels, which is part of the body''s normal healing and maintenance. The body grows new blood vessels in wound healing, and as collateral circulation around blocked or atherosclerotic blood vessels.

The main side effects are hypertension and heightened risk of bleeding. Bowel perforation,Fatigue and infection are also common. In advanced lung cancer, less than half of patients qualify for treatment.Nasal septum perforation and renal thrombotic microangiopathy ..

Mechanism of action
Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a growth factor protein that stimulates angiogenesis in a variety of diseases, especially in cancer.

Approval
It received its first approval, for combination use with standard chemotherapy for metastatic colon cancer.It approved for use in certain lung cancers, renal cancers, ovarian cancers, and glioblastoma multiforme of the brain.

The drug remains approved for breast cancer use in other countries including Australia.
The European Commission approved bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer.
In 2008, the FDA approved bevacizumab for use in breast cancer. 
In 2011, the US Food and Drug Administration removed bevacizumab indication for metastatic breast cancer after concluding that the drug has not been shown to be safe and effective. The specific indication that was withdrawn was for the use of bevacizumab in metastatic breast cancer, with paclitaxel for the treatment of people who have not received chemotherapy for metastatic HER2-negative breast cancer.
Request
Callback


Additional Information:

  • Packaging Details: 400mg, 100mg inj
Yes! I am Interested

Abirapro (Abiraterone Acetate) 250mg

Abirapro (Abiraterone Acetate) 250mg
  • Abirapro (Abiraterone Acetate) 250mg
  • Abirapro (Abiraterone Acetate) 250mg
  • Abirapro (Abiraterone Acetate) 250mg
Get Best Quote
Approx. Price: Rs 100 / PieceGet Latest Price

Product Details:

Packaging Size120 tab 250mg
BrandAbirapro
CompositionAbiraterone
ManufacturerGlenmark
Treatmentmetastatic castration-resistant prostate cancer (mCRPC) & metastatic high-risk castration-sensitive
FormTablet
Therapeutic Usesmetastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitiv
Interactionshypersensitivity to abiraterone acetate
Side Effecttiredness,vomiting,headache,joint pain,high blood pressure,swelling,low blood potassium
Strength120tab 250mg

Abiraterone,is used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).

Medical uses - Prostate cancer
Abiraterone is used in with prednisone, a corticosteroid, as a treatment for mCRPC .This is a form of prostate cancer that is not responding to first-line androgen deprivation therapy or treatment with androgen receptor antagonists. Abiraterone has received Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA)  and Therapeutic Goods Administration (TGA) approval for this indication.In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat mCRPC and given in combination with prednisone/prednisolone (subject to the conditions that the patient is not receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone has commenced).

Abiraterone may be useful for prevention of the testosterone flare at the initiation of GnRH agonist therapy in men with prostate cancer.

In people previously treated with docetaxel survival is increased by 3.9 months (14.8 months versus 10.9 months for placebo).

In people with castration-refractory prostate cancer but who had not received chemotherapy those who received abiraterone had a progression-free survival of 16.5 months rather than 8.3 months with placebo. After a median follow-up period of 22.2 months, overall survival was better with abiraterone.

Abiraterone, the active metabolite of abiraterone , inhibits CYP17A1, which manifests as two enzymes, 17α-hydroxylase (IC50 = 2.5 nM) and 17,20-lyase (IC50 = 15 nM) (approximately 6-fold more selective for inhibition of 17α-hydroxylase over 17,20-lyase) that are expressed in testicular, adrenal, and prostatic tumor tissues. CYP17A1 catalyzes two sequential reactions: (a) the conversion of pregnenolone and progesterone to their 17α-hydroxy derivatives by its 17α-hydroxylase activity, and (b) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by its 17,20-lyase activity. DHEA and androstenedione are androgens and precursors of testosterone. Inhibition of CYP17A1 activity by abiraterone thus decreases circulating levels of androgens such as DHEA, testosterone, and dihydrotestosterone (DHT). Abiraterone , via abiraterone, has the capacity to lower circulating testosterone levels to less than 1 ng/dL (i.e., undetectable) when added to castration.These concentrations are considerably lower than those achieved by castration alone (~20 ng/dL). The addition of abiraterone to castration was found to reduce levels of DHT by 85%, DHEA by 97 to 98%, and androstenedione by 77 to 78% relative to castration alone.In accordance with its antiandrogenic action, abiraterone  decreases the weights of the prostate gland, seminal vesicles, and testes.
Request
Callback


Additional Information:

  • Packaging Details: 120 tab 250mg bottle
Yes! I am Interested

Curcumin - Curgneet Liquid

Curcumin - Curgneet Liquid
  • Curcumin - Curgneet Liquid
Get Best Quote
Approx. Price: Rs 10 / BottleGet Latest Price
Request
Callback


Additional Information:

  • Minimum Order Quantity: 100 Bottle
Yes! I am Interested
X

Explore More Product



Reach Us
Aptcash Enterprises (Proprietor)
Aptcash Enterprises
Shop No. 7, B Wing, Nirmala Niwas, Aai Mai Merwanji Road
Parel, Mumbai - 400012, Maharashtra, India


Call Us
View Mobile No.


Send E-mailSend SMS